Good morning or good afternoon, all, and welcome to the Ingevity Fourth Quarter and Full Year 2021 Earnings Webcast. My name is Adam and I'll be your operator today. I will now hand you over to Mary Hall to begin. So Mary, please go ahead when you are ready.

Yes. Thank you, Adam. Good morning, all. Welcome to Ingevity's Fourth Quarter and Full Year 2021 Earnings Call. Early this morning, we posted a presentation on our investor site that you can use to follow today's discussion. It can be found on ir.ingevity.com under Events & Presentations. Also, throughout this call, we may refer to non-GAAP financial measures which are intended to supplement, not substitute for comparable GAAP measures. Definitions of these non-GAAP financial measures and reconciliations to comparable GAAP measures are included in our earnings release and are also found in our Form 10-K. We may also make forward-looking statements regarding future events and future financial performance of the company during this call, and we caution you that these statements are just projections, and actual results or events may differ materially from these projections, as further described in our earnings release. Our agenda is on Slide 4. With me today are John Fortson, our President and CEO; Mike Smith, President of Performance Chemicals; and Ed Woodcock, President of Performance Materials. In addition, we have Rich White, Steve Hulme, and Erik Ripple available for questions and comments. John will review key accomplishments in 2021. I'll follow with highlights of our financial performance in Q4 and for the full year. Mike and Ed will review the performance of their business segments, and John will conclude with our outlook for 2022 and full year guidance. And with that, over to you, John.

Thanks, Mary, and good morning, everyone. Thank you for joining us this morning on what is obviously a busy news day, and we appreciate your interest in Ingevity as we report on what we feel was a strong 2021. If you turn to Slide number 5, I'll start by highlighting some of our accomplishments. As you've seen on the new landscape slide after our cover page, Ingevity's products touch our everyday lives in many ways. Our technologies really do purify, protect, and enhance the world around us, and we're doing this while maintaining a best-in-class profitable and growing company. Overall, I'm really proud of the way Ingevity performed for the year. We grew revenue by 14% and adjusted EBITDA by 6% over 2020, despite what was a dynamic business environment. We all know the supply chain and logistics challenges our industry faced. Ingevity did a terrific job driving revenue growth through both increased volume and price across our portfolio. Performance Chemicals saw a strong recovery from the pandemic-impacted 2020. Engineered Polymers, in particular, drove revenue increases by almost 50%, which is remarkable work by this team, and we thank them. Demand for our industrial specialties products continued to increase. Compared to the last several years, supply and demand are in a good spot across time chemical applications. This increased demand has translated into higher volumes and has allowed us to aggressively raise prices. Performance Materials performed well in the face of the microchip shortage. While Q1 2021 started strong, microchip issues plagued the global auto industry throughout the year before chip availability improved in Q4 2021. From our internal estimates, this resulted in roughly $60 million to $70 million of lost sales last year. However, we anticipate this will correct as auto industry production increases and microchip supplies normalize. Despite these hurdles, Performance Materials delivered impressive 40-plus percent segment EBITDA margins for both Q4 and the full year. We also leveraged operational excellence to serve customers and gain share. Our team continued to work safely in the face of first the Delta variant and then the Omicron variant of COVID-19. While our goal is always zero injuries, I am proud of our operations teams for working injury-free at all our global technical centers and over 50% of our manufacturing facilities. We jumpstarted continuous improvement projects across our plant network. This is an easy feat while wearing masks and with ongoing on-site testing. These projects are intended to drive down costs this year, increase efficiencies, and lead to better customer service. Finally, our supply chain excellence really is a competitive advantage for us. We are stepping in to support new and existing customers when others are unable to. Now is the time to gain market share, and we are doing just that. We have experienced significant share gains in our adhesives products as a direct result of these efforts. We continue to strategically invest in growth for our future. We completed alternative fatty acid production and saw the first sales of our new ALTAVEG product. We continue to assess other feedstocks and expect commercial sales to grow this year. Our Performance Chemicals team advanced their work in bioplastics and understanding the role our Engineered Polymers technologies can play in addressing the world's plastic pollution challenges. Our products are increasingly being recognized as a critical component in various biodegradable processes, and we recently received news that our products have passed tests for marine biodegradation, which will lead to future certifications that complement the industrial and home compostable certifications we already have. Also, we're excited about the product's potential to further grow in the auto industry and support electric vehicles. We continue to expand in market penetration of Engineered Polymers products due to their unique performance and sustainability attributes. We further improved our sustainable value proposition for shareholders and customers. We increased our key ESG ratings, particularly our S&P Global CSA and EcoVadis scores. More importantly, we advanced the role our products play in helping our customers achieve their sustainability goals. For example, a recently completed third-party product study shows that WestRez, our Performance Chemicals Adhesive Technology has a 62% lower in-life carbon footprint than petroleum-based alternatives. We increased the number of USDA certified bio-based products in our portfolio by 50%, bringing our total to 34 products that are recognized. A lot was accomplished in 2021, and we will do even more in 2022. I'll now turn the call over to Mary to review our fourth quarter and full year financial performance.

Thanks, John. Please turn to Slide 6 where I review our Q4 and full year financial performance. As John mentioned, sales were up 3% Q4-over-Q4 and 14% year-over-year as robust volumes in Performance Chemicals more than offset the volume decline in Performance Materials automotive emission products. Price increases were successfully implemented across all business lines. Significant price increases were necessary to mitigate the inflationary pressure on costs that intensified in the second half of the year. For example, year-over-year freight costs were up 30%, and energy costs ended the year almost 50% higher. Our SG&A costs were also up in 2021, as we returned to more normal commercial operations, including increased travel and entertainment and spending on growth initiatives. Despite the dual challenges of sharply rising costs and the impact of the microchip shortages reducing our high-margin auto emission product sales, we delivered record adjusted EBITDA of $422 million and adjusted earnings per share of $5.23, with an adjusted EBITDA margin of 30.3%. On Slide 7, we've laid out certain key financial metrics and highlights. You can see our sales and adjusted EBITDA trends since 2016 in the top left chart, with sales growing at a compound annual growth rate of 9%, while we grew adjusted EBITDA margins from percentages in the low 20s to north of 30%. Our margin dip in 2021 to 30.3% reflects the impact of the steep drop in volume of our auto emission product sales and rising costs as I mentioned earlier. Our adjusted earnings per share of $5.23 reflects a compound annual growth rate of over 20% since 2016 and an increase of over 6% compared to 2019's strong performance. Free cash flow was down as expected compared to 2020's COVID-impacted level but was up more than 17% from 2019. Q4 inventory build in Performance Chemicals in anticipation of seasonal demand and continued strong volume growth resulted in free cash flow slightly below our guidance for the year. Our capital allocation continues to balance growth with returning capital to shareholders. In 2021, 40% of our capital expenditures were on growth projects with a similar spend on our strategic investments in GreenGas and other ventures. In addition, we repurchased over 1.4 million shares for about $109 million. Since our 2020 Board authorization, we have repurchased a total of approximately three million shares for just under $200 million. Our strong cash flow allowed us to fund our growth initiatives and share repurchases, while also reducing leverage to 2.2x net debt to adjusted EBITDA from 2.5x at year-end 2020. We believe this balanced and disciplined approach to capital allocation serves all our stakeholders well. I'll turn it over to Mike for more color on Performance Chemicals segment results.

Thanks, Mary. I'll continue on Slide 8. Our Performance Chemicals segment saw strong revenue growth and continued increased demand and improved pricing in the quarter, with both Industrial Specialties and Engineered Polymers benefiting from a robust sales environment throughout the year. Segment sales were up 24%, both quarter-over-quarter and for the full year at $204 million and $875 million, respectively. Industrial Specialty sales increased 28% compared to the prior-year quarter, with strong performance across all markets. Sales growth in adhesives, TOFA, and disbursements all increased by over 30% versus Q4 2020. Oilfield applications delivered particularly strong growth, with sales up over 50% in the quarter due to the increase in North American drilling activity and our growth in sales to the Middle East. In addition to solid volume growth from increased demand in key industrial specialty applications, price increases averaged over 20% in the quarter. The supply-demand environment remains favorable as Chinese gum rosin prices are still 50% above levels in late 2020 and vegetable-based fatty acid pricing continues to increase significantly compared to early 2021 levels. Our agricultural chemical business saw increased demand due to further adoption of our sustainable technologies across the market segment. We continue to see positive outcomes from late-stage field trials underway with major agricultural customers. We also sold non-CTO based alternative fatty acids and alternative fatty acid derivatives in Q4. We remain excited about the additional alternative fatty acid capacity at our Crossett facility coming online in early Q2 of this year to support substantial future sales growth. Pavement Technologies had a record Q4 with sales up 11%, mainly driven by pavement preservation volumes. The business also saw the successful introduction of new product launches during the quarter. The strong finish to the year resulted in our pavement technology business achieving its 10th straight year of sales growth, a great milestone demonstrating the value of our innovative, sustainable paving solutions and the strength of our team. We continue to be pleased with our Engineered Polymer business, which grew 22% Q4-over-Q4 as we continue to experience growth in automotive, industrial equipment, and footwear and apparel. Revenues were boosted by further price increases to offset inflationary costs for raw materials logistics and energy that spiked in Q4. As John and Mary shared, the Engineered Polymers team delivered an impressive 46% increase in full-year sales, showing growth in all regions and largely the same markets that drove Q4 growth. Energy, raw materials, and logistics costs continue to increase, and the ability to move products efficiently around the globe remains challenged, but price increases allowed us to offset these inflationary impacts in the fourth quarter. Performance Chemicals EBITDA of $22 million in Q4 was down 19% compared to the prior-year quarter due primarily to inflationary cost pressures and increased SG&A investments. Full year EBITDA increased 16% versus the prior year, as price and volume improvements more than offset inflationary cost pressures. I'll now turn the call over to Ed to discuss Performance Materials' results.

Thanks, Mike. If you'll turn to Slide number 9, sales for the Performance Materials segment were down 18% at $132 million compared to our all-time record quarter in Q4 2020 when the automotive industry rebounded sharply post the initial pandemic lockdowns. In the quarter, our automotive-related product sales were impacted by lower vehicle production, driven by the ongoing chip supply constraints. With lower production volumes of our automotive products, our mix shifted towards our lower-value water, food, and beverage purification markets. Sequentially, in comparison to Q3 2021, our Q4 revenue was up 11.8%, as North America and China vehicle production rose 11% and 39%, respectively, during the quarter. The sequential increase was driven by the clearance of the Southeast Asia COVID microchip backlog that began to correct in early October and generated chip supply into Q4. Still, hovering at low levels, North American vehicle production fell 15% versus Q4 2020, and December U.S. light vehicle inventories remain well below December 2019 and 2020 levels. Chinese light vehicle production and sales in the quarter were down 2% and 5%, respectively, compared to prior periods. North American Q4 vehicle production remains at a favorable mix of 81% trucks and SUVs to 19% sedans, which closely tracks with the full-year mix of 80% trucks and SUVs to 20% sedans. OEMs continue to direct their limited microchip volumes to their most profitable vehicles, pickups, and SUVs. For the full year, our sales of $517 million were up slightly, primarily due to price increases. Our segment EBITDA of $249 million was almost even with 2020. Despite the supply chain challenges throughout the year, we maintained a solid 48% segment EBITDA margin for the year. Based on IHS data, we estimate the full-year impact of microchip-related production losses to be about $60 million to $70 million in revenue for Ingevity. We expect microchip supplies to continue to be constrained throughout 2022. Lastly, U.S. and Canada Tier 3 implementation is ongoing as some model year 2022 platforms were delayed by the pandemic. Remaining Tier 3 implementations should be completed in early 2022. I'll turn the call back over to John to discuss our guidance for 2022.

Thanks, Ed. On Slide 10, I'd like to review our outlook for 2022. Our guidance for 2022 is that sales will be between $1.525 billion and $1.6 billion and adjusted EBITDA will be between $430 million and $460 million. This guidance for both revenue and EBITDA is fairly broad to reflect a wide range of potential outcomes in the Performance Materials segment. In the Performance Chemicals segment, we expect revenue growth from higher volumes and continued price increases across all product lines to offset continued cost pressure. While Performance Chemicals margins were down in Q4 of 2021, we expect them to normalize this year as cost increases plateau. Industrial Specialties and Engineered Polymers are off to a great start this year. While it's too early in the year to measure pavement technologies, we believe we'll see good growth as countries globally expand their paving operations. The outlook for Performance Materials is less certain. The forecast for 2022 auto production is conservative due to the ongoing microchip shortage and other auto supply chain issues. Q4 2021 chip availability improved from Q3, but we're not confident that a sustainable rate of supply has been achieved. For 2022, the lower end of our range assumes continued supply constraints in the first half of the year, followed by some recovery in the second half. To the extent industry dynamics improve and recover sooner, we would end up at the higher end of our range. We will continue to invest organically as we bring online our new polyol capability in DeRidder and an alternate fatty acid stream in Crossett. Additionally, we are working on several debottlenecking projects at our Performance Materials facilities. We are also in the execution phase of our SAP S/4HANA implementation. Capital expenditures will be elevated somewhat from recent levels, but we consider these investments well worth the effort as they exceed our investment return expectations and will help us sustain our highly profitable growth. Finally, we will continue to return capital to shareholders, as we see opportunities to buy back shares at what we consider attractive levels. I am confident our team will deliver a strong performance this year. Before we go to Q&A, I would like to take a moment to thank Mike Smith for her service to Ingevity. This will be her last earnings call. Going forward, you will hear from Rich and Steve. Mike, while we know we will still see you around, we thank you and wish you the best of luck. In closing, I appreciate the ongoing hard work and efforts of all of our employees worldwide. We hope you share our enthusiasm for Ingevity. Now, at this point, we'll take your questions.

The first question today comes from Vincent Anderson of Stifel. Vincent, please go ahead. Your line is open.

Hi. Good morning. Can you hear me okay?

You broke up just a little bit, but go ahead.

All right. I’ll give it a shot, yell at me if it keeps breaking up. Can you speak to the revenue mix in Engineered Polymers this quarter between monomer, raw material pass-through, and derivatives, and where that could trend over the course of 2022, as it relates to your margin expectations on that business?

Yeah, thanks. So in general, our mix for derivatives versus monomers, we expect that to continue to lean more towards derivatives. From a volume standpoint, that mix didn't change too much in 2021, as all areas of the Engineered Polymers business grew quite significantly. But as we described over time, our focus and working closely with our customers is to continue to drive derivative sales in both polyols and thermoplastics. As evidence of that, of course, we're very much looking forward to getting the start-up of our new polyol facility in DeRidder here in the middle of this year.

Okay. Thank you. And can you just staying on Performance Chemicals, could you discuss your CTO costs and, importantly, your availability heading into 2022 on the portion of your supply that is not covered under long-term agreements?

Yeah. So we had anticipated and we're seeing raw material cost inflation on CTO. In terms of availability, we anticipate being able to get what we planned for. That's what we entered the year believing in our outlook for the year continues to demonstrate that.

Put another way, Vincent, of the 320,000 tons of materials we are utilizing, nearly all of it for the year is under contract except for about 15,000. So as we enter the year, which is generally the case, we have strong visibility for 2022.

Yeah. And I guess the other thing to add, as was mentioned in the script, we've anticipated the inflation, and we're seeing that inflation. From a market standpoint, our price increases continue to go very well, and we believe in the pine chemicals market, we're going to be able to more than offset any inflation in CTO with price increases during 2022.

Okay. Great. Thanks. If I could ask one more briefly on Performance Materials. I'm just wondering if there's any progress you can share on your A&G technology? And have conversations changed at all, particularly on the fleet conversion side as we've seen fuel prices surge recently?

Yes, Vincent, this is Ed. We see significant opportunities ahead with the fleets we are working with, which include over 50 fleets from natural gas utilities to municipalities and energy companies. However, we face the same challenge nationwide: the limited availability of pickup trucks. Once production increases and we can build up our truck inventories, we anticipate being able to grow not only the number of fleets but also the volume each fleet will use in their respective industries.

All right. Great to hear. Thanks again, and good luck on the rest of the year.

Thanks.

Thank you.

The next question comes from Jonathan Tanwanteng from CJS Securities. Jon, your line is open. Please go ahead.

Hi. Good morning. Thank you for taking my question.

Hi, Jon.

I was wondering if you can hear me?

Yeah.

Hello.

Go ahead, Jon.

Okay. Thank you. I was wondering what the exact expectations for auto unit sales were within the ranges of your guidance, the practice, I guess, that you're thinking about?

Yeah, John, this is Ed. Typically, when we're looking at auto volumes, we primarily focus on our highest value market, and that would be North America. Right now, I would say we ended up in 2021 at 13 million vehicles in North America being produced. IHS's forecast is currently 15.2 million vehicles for 2022, and so we're effectively following IHS numbers as far as what we are plugging into our economics for the full year of 2022.

Okay. Great. And then I was just wondering if you guys had any commentary, just on any exposure to Eastern Europe and the conflicts there, either on the supply and demand side just have you thought about that? What are you doing to mitigate that risk?

Sure. I want to address that question more broadly. As you all know, we feel fortunate that our business is primarily focused in the U.S., with Europe making up about 16% of our sales. We've examined Eastern Europe as a whole, which includes countries neighboring the former Soviet Union, and found that Russia accounts for roughly 4% of our sales. While there is some automotive production in Poland, it is not being significantly impacted by the situation in Ukraine. We do acknowledge that disruptions in global markets could have some effects on us, but directly, the events in Ukraine will not affect Ingevity.

Okay. Great. And if I could sneak one more in there. Just any update on the Euro 7 mandate and when they might be officially set?

Yeah, go ahead, Ed.

Yeah, this is Ed. I want to discuss Brazil first regarding the implementation of new regulations. We anticipate that as these are put into place this year, we will increase our revenue from low single-digit millions last year to high single-digit millions. We're observing positive regulatory growth in Brazil. The Euro regulations are still in the review phase, with the first draft expected in June. We will figure out what that means for us around the middle of the year. Concerning China and the China 7 initiative, which is essentially adopting a Tier 3 U.S. model, we still foresee implementation occurring around 2026 at the earliest. However, with Brazil already implementing, Europe considering it, and China also moving in this direction, we are very optimistic about seeing substantial regulatory growth over the next few years.

Okay. Great. Thank you.

Our next question is from Mike Sison from Wells Fargo. Mike, please go ahead. Your line is open.

Hey, good morning. Congrats on the strong end of the year. I guess for Performance Materials, did a really nice job in getting pricing. How much of that pricing flows through into 2022? And do you need to seek more pricing if the inflation outlook gets worse from here?

Yeah. This is Ed. We've obviously had a very sizable price implementation, and it kind of doubled over. We had two price increases that compounded last year. We do have more pricing coming in this year, and we'll continue to add price across our business as necessary.

Okay. And then in terms of the guidance for 2022, when I think about Performance Materials, do you get most of the EBITDA growth in the second half of the year given the commentary that you still have some microchip issues in the first half?

Yeah, Mike, I mean I think of it as being sort of symmetric, right? I mean, if Q1 and Q2 were strongest last year, Q3, Q4 weaker, our guidance sort of assumes a reversal of that. So a weaker Q1 and Q2 with some improvement in Q3 and Q4. As I said in my prepared comments, to the extent this happens quicker or with more force, we would see ourselves moving towards the higher end of that guidance. As we mentioned, our best estimates suggest that about $60 million or $70 million of revenue was lost this year because of this. So that should give you some sense of the order of magnitude of what the snapback could look like. It's just a question of how that sequences in over time.

Right. Right. Okay. And then just one follow-up on Performance Chemicals in terms of pricing as well. Again, another good quarter there in terms of pricing. Did you fully offset inflation? Does it become incremental to EBITDA as we head into the first half of the year, or is it more catch-up and then maybe a little bit more incremental in the second half of the year?

Yeah, I actually think the pricing overall for the year, the pricing improvement in dollars will more than offset those inflationary costs in energy, raw materials, logistics, etc. As you can see from the trajectory, essentially half of the price increase for the entire year occurred in the fourth quarter. I think that from a comparative basis, we're going to start to see a significant price increase against the prior year as we start 2022.

The next question comes from Paretosh Misra from Berenberg. Paretosh, your line is open. Please go ahead.

Thanks, and good morning everyone. What are you seeing in your energy business? Are you anticipating an improvement in sales this year versus last year?

Absolutely. That would be correct, yes. Absolutely. We had a great Q4. The outlook this year versus last year looks very strong. It's as much a matter of supporting our highest margin business and really pushing a price increase across all the pine chemical businesses, which of course includes our oilfield business.

Got it. And how should we think about margins in your two segments in going from Q4 to Q1 given all these moving parts regarding inflation and whatnot? Are you expecting margins to improve as we get into Q1 on a sequential basis?

Yeah. I mean, Paretosh, as you know and we've said this for years, you've got to be very careful looking at our business quarter by quarter because, a, you've got that sort of asphalt seasonality that goes in. And then b, the businesses, Engineered Polymers is a good example. It's a call it $185 million, $200 million business. If it takes an outage, it can have an impact in any given quarter. So you've got to be sensitive to that. What I would say is, as we talked about, I think our expectation is that in Q1, the Performance Chemicals segment will move to more normalized margins from what you saw in Q4. There are a couple of reasons for that. We had some downtime in the UK in Engineered Polymers, and asphalt winds down. It's typically our weakest quarter for margins. But we see Q1 normalize into what I would say is a more normalized run rate margin for that business relative to an annual basis, recognizing that the first quarter is a little weaker than the average for the year. Another way of thinking about that is that revenues are going to catch up with some of the prices. The price increases will take hold relative to some of the costs that they've dealt with. Regarding PM, it's really not going to be that different from where we sat in Q4 of this year.

Got it. Thanks a lot. And maybe if I could ask one last one. With regard to your activated carbon for methane capture applications, can you provide some color as to what you're seeing there, and if you're factoring in any sales to that market in your forecast for this year?

We're not really factoring in direct sales this year, although we may get some. Our green gas initiatives are frankly ahead of plan and they continue to have opportunities, and you will probably see us continue to invest in that business and others like it. But we take a pretty conservative approach, Paretosh, forecasting. To the extent things are accelerated there, that would be upside to the forecast we have. We see it being more of a revenue contributor in 2023 and 2024.

Thanks, John. All the best for the year.

Yeah. Thank you.

Our next question comes from John McNulty of BMO Capital Markets. John, your line is open. Please go ahead.

Hey, John.

Hi. This is Caleb on for John. Hope that's all right.

That's all right. Go ahead.

Thanks, and congrats on the quarter. I just had a really quick question. I believe in your prepared remarks you signaled that you had some share gains in adhesives. I was just wondering if you could unpack that a little bit?

Sure. Adhesives present a significant market opportunity for us. The adhesive market is extensive with many different types available. Historically, we have focused more on other applications rather than directly competing in adhesives. This year, our Industrial Specialties team did an excellent job meeting customer needs in a challenging environment, which allowed us to gain market share. We anticipate maintaining and expanding that share as we have a substantial opportunity ahead. Our adhesives business is about one-fifth or one-sixth the size of one of our competitors, which gives us room to grow, and we plan to pursue this aggressively. Rich, do you have anything else to add?

No. But thanks for the question, John. Our adhesives business, as you probably already know, is heavily weighted towards the road striping aspect of the business. Certainly, we've seen expansive growth in the packaging side, particularly into the Asian markets and in Europe in this last year. So we're really excited about that. As John said, we still see a wealth of opportunity out there for this particular area of business for us. Thank you.

Okay. Thank you.

Thank you all. This concludes our call, and thank you for your interest in Ingevity.

This concludes today's call. Thank you very much for your attendance. You may now disconnect your lines.